8-K

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): July 23, 2013

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                  614 Mckinley Place NE
                  Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))







Item 8.01  Other Events

A copy of the press release issued by Techne Corporation on July 23, 2013,
announcing the appointment of Dr. J. Fernando Bazan as Chief Technology
Officer is attached hereto as Exhibit 99.1.



Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated July 23, 2013.








                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: July 23, 2013                  TECHNE CORPORATION
                                      By: /s/ Charles R. Kummeth
                                      ---------------------------
                                      Name: Charles R. Kummeth
                                      Title: Chief Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------

    99.1 Press release of Techne Corporation dated July 23, 2013.

EX-99.1

            TECHNE CORPORATION APPOINTS DR. J. FERNANDO BAZAN
                     AS CHIEF TECHNOLOGY OFFICER

Minneapolis, Minnesota - July 23, 2013 - Techne Corporation (NASDAQ: TECH)
(Techne) announced today that J. Fernando Bazan, Ph.D. has been appointed
Chief Technology Officer. With global recognition as a scientific leader in
fields ranging from structural biology to drug discovery for the treatment of
human disorders, Dr. Bazan will be instrumental in directing innovation and
influencing future growth in Techne's world-wide market.

Dr. Bazan joins Techne with more than twenty years of experience in academia
and the biotechnology industry. Following training at Stanford University,
the University of California Berkeley, and the University of California San
Francisco, he served as a senior scientist at the DNAX Research Institute
(Schering-Plough/Merck) and at Genentech (Roche) as well as serving as Chief
Scientific Officer at NeuroScience, a neuroimmunology startup. Dr. Bazan
holds an adjunct faculty appointment at the University of Minnesota School of
Medicine where he applies pharmacological approaches to cancer and immune
disorders and utilizes structural and computational insights to investigate
signaling mechanisms in biological systems.

As a world renowned scientist, Dr. Bazan has shed light on important
biological questions and set the groundwork for advances in the cell
signaling and immunology fields. His technical expertise, interdisciplinary
approach, and creativity led to the first classification system of the
structural architectures of cytokines and their receptors. Dr. Bazan's
research also produced numerous scientific breakthroughs including the
identification of novel cytokines, their receptor complexes, and immune
subsets (Th17 cells) that responded to these factors. This ability to drive
global technical collaborations will help frame the strategic and platform
decisions for the Company.

"We are delighted to welcome Dr. Bazan to the executive team at Techne," said
Charles R. Kummeth, President and Chief Executive Officer of Techne. "His
seminal discoveries of key cytokines are central to our business, and Dr.
Bazan brings with him the technical expertise and vision to help lead the
future of innovation at Techne."


-----------------------------------------



TECHNE Corporation and Subsidiaries (the Company) are engaged in the
development, manufacture and sale of biotechnology products and hematology
calibrators and controls. These activities are conducted through the
Company's two operating subsidiaries: Research and Diagnostic Systems, Inc.
(R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D
Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of
biological products. R&D Systems has three subsidiaries: BiosPacific, Inc.
(BiosPacific), located in Emeryville, California, Boston Biochem, Inc.,
located in Cambridge, Massachusetts, and R&D Systems China Co. Ltd., (R&D
China), located in Shanghai, China. BiosPacific is a worldwide supplier of
biologics to manufacturers of in vitro diagnostic systems and
immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer
of ubiquitin-related research products. R&D China and R&D Europe distribute
biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd.
(Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.
Tocris is a leading supplier of chemical reagents for non-clinical life
science research.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854